Status:
RECRUITING
Study of BHV-1300 in Graves' Disease
Lead Sponsor:
Biohaven Therapeutics Ltd.
Conditions:
Graves Disease
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Eligibility Criteria
Inclusion
- Key
- 1\. Participants must have serologically confirmed Graves' Disease.
- Key
Exclusion
- History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.
- History of treatment with radioactive iodine or thyroid surgery.
Key Trial Info
Start Date :
August 21 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06980649
Start Date
August 21 2025
End Date
March 1 2026
Last Update
November 24 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Site-103
South Gate, California, United States, 90280
2
Site-100
Miami, Florida, United States, 33126
3
Site-104
Columbus, Georgia, United States, 31904
4
Site-106
Houston, Texas, United States, 77054